Health
Canopy Biosciences develops spatial proteomics assay for COVID-19 – News-Medical.Net
Canopy Biosciences, a Bruker Company, today announced the successful development of a new assay for examining immune response to COVID-19.
Canopy Biosciences, a Bruker Company, today announced the successful development of a new assay for examining immune response to COVID-19. The assay uses high-plex spatial proteomics and is performed on Canopy’s ZellScannerONE precise spatial phenotyping instrument. ZellScannerONE enables multiplexed spatial quantification of protein biomarkers in tissue samples, as well as in suspended cells. Relative to traditional techniques, such as flow cytometry, Canopy’s ChipCytometry is able to detect and…
-
General20 hours agoAustralian celebrity chef Peter Russell-Clarke dies aged 89
-
Noosa News24 hours agoSouth-west Queensland highway closed after truck carrying oxygen cylinders catches fire
-
General22 hours agoBack-to-back rate cuts tipped when Reserve Bank meets
-
Noosa News22 hours agoWoman left with significant arm injuries in lion attack at Darling Downs Zoo in Queensland